Skip to main content

Tate Michael Truett's Form 4/A amendment

Amended

Astera Labs, Inc. (ALAB) · filed Aug 20, 2025

Accession no.
0001736297-25-000108
Filed
Aug 20, 2025
Trade date
Aug 7-8, 2025
Filing delay
13 days
Rule 10b5-1 plan
Not checked
Original filed
Aug 11, 2025

This filing lists 6 non-derivative transactions. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $17.1M. It was filed 13 days after the trade.

This amendment restates part of 0001736297-25-000102 (filed Aug 11, 2025). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tate Michael TruettCIK 0001399546Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 7, 2025Common StockSSaleDisposed−43,184$169.61F1−$7,324,438.24575,812Indirect
Aug 7, 2025Common StockSSaleDisposed−7,550$170.34F3−$1,286,067568,262Indirect
Aug 7, 2025Common StockSSaleDisposed−15,141$171.48F4−$2,596,378.68553,121Indirect
Aug 7, 2025Common StockSSaleDisposed−34,125$173.82F5−$5,931,607.5518,996Indirect
Aug 7, 2025Common StockGGiftDisposed−7,500$0.00$0511,496Indirect
Aug 8, 2025Common StockGGiftDisposed−10,000$0.00$0501,496Indirect

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001736297-25-000102 (filed Aug 11, 2025).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001736297-25-000102
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 7, 2025Common StockGGiftAcquired+7,500$0.00$07,500Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.0500 to $169.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.0500 to $170.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.0800 to $171.8500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.5950 to $174.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

Represents a bona fide gift of shares to a non-affiliated entity.

F7

Represents a bona fide gift of shares to a non-affiliated person.

Remarks

This Form 4/A (this "Amendment") amends and restates in its entirety the original Form 4 filed with the U.S. Securities and Exchange Commission on August 11, 2025 (the "Original Form") to remove the transaction relating to the acquisition of Astera Labs, Inc. common stock ("Common Stock") by GlobalStar Donor Advised Fund ("DAF"), of which the Reporting Person was inadvertently reported due to administrative error as being a trustee. In fact, the Reporting Person has no pecuniary interest in GlobalStar DAF; as such, the 7,500 shares were gifted to and acquired by a non-affiliated entity, as reported in this Amendment.

Read the full filing on SEC EDGAR (opens in a new tab)